School of Biomedical Sciences
生物醫學學院
The Chinese University of Hong Kong 香港中文大學

李家樂


Dr LEE Carol

助理講師

B.Sc. in Molecular Biotechnology, School of Life Sciences, CUHK
Ph.D. in Surgery, Faculty of Medicine, CUHK

電話:  3943 6817

電郵:  Email住址會使用灌水程式保護機制。你需要啟動Javascript才能觀看它

地址:

地址:610U, Choh-Ming Li Basic Medical Sciences Building

 

 

 

個人簡介

Dr. LEE Carol (李家樂) obtained her B.Sc. in Molecular Biotechnology (First Class Honors) and Ph.D. in Surgery from The Chinese University of Hong Kong (CUHK). She then worked in the biopharmaceutical industry before returning to CUHK as a postdoctoral researcher in the School of Biomedical Sciences (SBS). Dr. Lee has strong expertise in molecular biology, cancer biology and therapeutics. Her research focuses on deciphering oncogenic drivers and developing novel precision medicine strategies, including targeted therapy and cell-based immunotherapy, particularly in the context of liver cancer and lung cancer. Dr. Lee is passionate about teaching, mentorship and science communication. She has served as an advisor to undergraduate FYP students and the CUHK iGEM team. She has also received awards in science communication contests and has organized and hosted various academic conferences. Her teaching interests cover pharmacology and physiology.

  1. Course coordinator - PHAR3420.
  2. Pharmacology and physiology courses.
  3. Cancer biology and therapeutics.
  1. Lee C, Chen X, Mu W, Tsui SKW. ARAF p.S214C mutation enhances sorafenib response in lung cancer. 2024 Korean Association for Lung Cancer International Conference. 2024. Conference Abstract - Best Poster Presentation Award.
  2. Deng M, Cai H, He B, Guan R, Lee C, Guo R. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization, potential conversion therapies for single huge hepatocellular carcinoma: a retrospective comparison study. International Journal of Surgery. 2023;10:1097.
  3. Lee C, Chan SM, Yeung SF, Tsui SKW. Targeting ARAF p.S214C mutation with sorafenib in non-small cell lung cancer. 2023 Annual Meeting of the American Association for Cancer Research. 2023. Conference Abstract.
  4. Deng M, Lei Q, Wang J, Lee C, Guan R, Li S, Wei W, Chen H, Zhong C, Guo R. Nomograms for predicting the recurrence probability and recurrence-free survival in patients with hepatocellular carcinoma after conversion hepatectomy based on hepatic arterial infusion chemotherapy: a multicenter, retrospective study. International Journal of Surgery. 2023;10:1097.
  5. Lee C, Chan SL, Chan WH, Cheung TT, Chong CN, Ng WC, Lai BS, Law HL, Li TC, Ng KC, Or YL, Yeung C, Xu MJ, Cheung ST. STAT3 regulates chemo-resistance and cancer stemness in hepatocellular carcinoma. 2020 Annual Meeting of the American Association for Cancer Research. 2020. Conference Abstract.
  6. Lee C, Cheung ST. STAT3: An emerging therapeutic target for hepatocellular carcinoma. Cancers. 2019;11(11):1646.
  7. Fung SW, Cheung PFY, Yip CW, Ng LWC, Cheung TT, Chong CCN, Lee C, Lai PBS, Chan AWH, Tsao GSW, Wong CH, Chan SL, Lo WS, Cheung ST. The ATP-binding cassette transporter ABCF1 is a hepatic oncofetal protein that promotes chemoresistance, EMT and cancer stemness in hepatocellular carcinoma. Cancer Letters. 2019;457:98-109.
Y. He, L. Zhu, J. Ma, L. Wong, Z. Zhao, Y. Ye, P.P. Fu and G. Lin* (2020). Comprehensive investigation and risk study on pyrrolizidine alkaloid contamination in Chinese retail honey. Environmental Pollution. 267, 115542.